# Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

> **NCT01494987** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 431 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Placebo
- **DRUG:** Glimepiride
- **BEHAVIORAL:** Diet
- **BEHAVIORAL:** Exercise

## Key facts

- **NCT ID:** NCT01494987
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 431 (ACTUAL)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01494987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01494987, "Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01494987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*